HIV Incidence Products
Our HIV incidence assays are used to estimate the rate of new HIV infections and monitor the epidemic worldwide.
Rapid Point-of-Care Assays
Sedia develops, markets and licenses rapid point-of-care immuno- diagnostic tests, including oral and other alternative fluid specimens
Specimen Collection Devices
Sedia's specimen collection devices are simple to use, economical and provide quality specimens suitable for a variety of assay technologies
DNA Sequencing Services
Our subsidiary, Floragenex, provides expert next generation DNA sequencing, genotyping and analytics.

Statement Regarding Sedia's Role in Novel SARS-CoV-2 Whole Genome Sequencing for Novel Variant Detection and Surveillance

From Dr. Clay Roscoe, Chief Medical Officer, Sedia Biosciences:


“Presently, SARS-CoV-2 variants from the UK, South Africa and Brazil have been identified in the U.S., along with several additional variants of interest or concern that have emerged domestically. Many of these variants have been shown to spread more easily and we continue to not fully understand how widely these variants have spread in-country, how the disease caused by these variants differs from other variants currently circulating, or how these variants may affect existing therapies, vaccines, and diagnostic tests. An affordable and accurate genomic surveillance service can assist with the detection and monitoring of novel variants and will be important in our ongoing response to the COVID-19 pandemic, here in the U.S. and globally”


To support this need Sedia Biosciences will now provide whole genome sequencing services of the SARS-CoV-2 virus in COVID-19 positive samples to support monitoring and surveillance programs in the U.S. and around the world.  The service will provide a Research Use Only tool to enable Public Health monitoring of SARS-CoV-2 variants in the population and is not intended for diagnostic use.


How it works:

   1.  Contact our Customer Service Department at
   2.  Complete the required documents for sample submission
   3.  We will send you a sample transfer kit
   4.  Once you receive the kit, transfer your samples
   5.  Clean the sample tubes and send in your samples
   6.  Data will be provided within 2-3 weeks of sample receipt

What you will receive:

   1.  All raw sequence files with intermediate files
   2.  Illumina Dragon software analysis and reports comparing your samples to known variants


For further questions contact our Customer Service Department at

Advancing Access to Care Through Innovation

Sedia Biosciences' mission is to advance global access to healthcare by developing innovative disease surveillance and monitoring tools, expanding accessible point-of-care diagnostic testing into both technology-rich and resource-limited settings and providing cost-effective specimen collection devices.

OUR Products & Technologies

HIV Incidence Assays

Enzyme immunoassays designed to distinguish recent HIV infections from long-term ones as a means to measure incidence of new HIV infections in populations.  We are also developing assays that will target recent infections which have the highest risk of transmission, which pose the greatest risk to others, to enable aggressive treatment, follow-up and customized therapy.

Rapid Point-of-Care Diagnostic Assays

Rapid cost-effective assays that provide diagnostic results from a variety of specimens, including whole and finger-stick blood, serum, plasma, oral fluid, urine and other clinical specimens.  Most of our assays are focused on infectious diseases. However, we are developing rapid assays that identify other disease markers as well.

Specimen Collection Devices

Devices intended to collect, stabilize and transport specimens from the point-of-care to the clinical laboratory.  Designed to be cost effective, robust and to provide a high yield of usable analytes, such as DNA, proteins, antibodies, enzymes and other biomarkers.  We also market low cost, easier-to-use alternatives to classical dried blood spot cards.


We have a variety of licensing and commercial partnership opportunities.  Our technologies are available for licensing to third parties interesting in expanding their technology portfolios, developing improvements to their own technologies, or seeking custom solutions to technological challenges they may encounter.  We are also experienced at commercializing third-party technologies for developers who are seeking to turn their prototypes into commercial products.

Latest News
| Home | About Us | Contact Us | Jobs | Privacy Policy | Terms and Conditions | Search | Site Map |     © Copyright 2018 - Sedia Biosciences Corporation